Kuros Biosciences treated the first patient in a prospectively designed, randomized controlled U.S. trial named PROOF, comparing MagnetOs Putty to autograft for posterolateral spine fusion.
This Level 1 quality trial will be the first such U.S. clinical study of MagnetOs for spinal fusion. The putty will be implanted on one side of the spine and the control material, autograft, on the contralateral side. Thirty patients will undergo a two-level instrumented posterolateral fusion.
Iterim analysis will occur once 15 patients have completed their six-month visit with available measurements for the endpoints.
Joost de Bruijn, Chief Executive Officer, said, “We are excited with the start of the clinical trial PROOF, as it aims to provide evidence to further differentiate MagnetOs and drive wider adoption in clinical practice across the globe. It is also an important step in our effort to improve spine fusion by bringing together an unprecedented blend of scientific, pre-clinical and clinical studies to make what can be an unpredictable process much more predictable. ”
Kuros Biosciences treated the first patient in a prospectively designed, randomized controlled U.S. trial named PROOF, comparing MagnetOs Putty to autograft for posterolateral spine fusion.
This Level 1 quality trial will be the first such U.S. clinical study of MagnetOs for spinal fusion. The putty will be implanted on one side of the...
Kuros Biosciences treated the first patient in a prospectively designed, randomized controlled U.S. trial named PROOF, comparing MagnetOs Putty to autograft for posterolateral spine fusion.
This Level 1 quality trial will be the first such U.S. clinical study of MagnetOs for spinal fusion. The putty will be implanted on one side of the spine and the control material, autograft, on the contralateral side. Thirty patients will undergo a two-level instrumented posterolateral fusion.
Iterim analysis will occur once 15 patients have completed their six-month visit with available measurements for the endpoints.
Joost de Bruijn, Chief Executive Officer, said, “We are excited with the start of the clinical trial PROOF, as it aims to provide evidence to further differentiate MagnetOs and drive wider adoption in clinical practice across the globe. It is also an important step in our effort to improve spine fusion by bringing together an unprecedented blend of scientific, pre-clinical and clinical studies to make what can be an unpredictable process much more predictable. ”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
